LOGO.jpg
Interpace Biosciences Enters into Agreement for $20 Million Investment from 1315 Capital and Ampersand Capital Partners
January 13, 2020 06:55 ET | Interpace Biosciences, Inc.
Reverse Stock Split Planned Concurrent with Closing Investment expected to support achieving cash flow break-even and accelerate Interpace’s growth plans and acquisition strategy Parsippany,...
LOGO.jpg
Interpace Biosciences Announces Collaborative Study with University of North Carolina to Assess the Use BarreGEN® after Ablation of Dysplastic Barrett’s Esophagus
January 06, 2020 06:55 ET | Interpace Biosciences, Inc.
Parsippany, NJ, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG), a leader in enabling personalized medicine, today announced that the Company’s wholly-owned subsidiary,...
LOGO.jpg
Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT®
December 17, 2019 06:55 ET | Interpace Biosciences, Inc.
Parsippany, NJ, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (Nasdaq: IDXG) today announced that its Medicare Administrative Contractor (MAC) has issued a new draft local coverage...
LOGO.jpg
Interpace Biosciences Expands Strategic Partnership Activities with Genecast Biotechnology in China
December 05, 2019 06:55 ET | Interpace Biosciences, Inc.
Further Strengthens Business Development Team with Key Hire PARSIPPANY, N.J., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Interpace Bioscience’s subsidiary, Interpace Pharma Solutions today announced...
Logo.png
Interpace Biosciences Launches New Corporate Website
December 02, 2019 06:55 ET | Interpace Biosciences, Inc.
PARSIPPANY, NJ, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (IDXG) announced today that it is launching its new corporate website, “Interpace.com”. Now both the Diagnostics and...
Logo.png
Interpace Diagnostics Changes Name to Interpace Biosciences; Announces Plans for Next Phase of Growth and Third Quarter 2019 Financial Results
November 13, 2019 16:40 ET | Interpace Biosciences, Inc.
Third Quarter Revenue Grew 34% Over the Prior Year’s Quarter and 25% Year to Date Acquired BioPharma Business in Partnership with Ampersand Diagnostic Test Volume Grew 16% for the Quarter and...
Logo.png
Interpace to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results on Wednesday, November 13, 2019
November 12, 2019 06:55 ET | Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will report its third quarter 2019 financial results on Wednesday, November 13, 2019 at 4:30 p.m. ET....
Logo.png
Interpace Diagnostics Announces Publication of New Data on Thyroid Test Utility
November 04, 2019 06:55 ET | Interpace Diagnostics Group, Inc.
Clinical Data Highlights the Utility of ThyGeNEXT® and ThyraMIR® PARSIPPANY, NJ, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Interpace Group (NASDAQ: IDXG) Interpace Diagnostics announced today the...
Logo.png
Interpace to Present Data at the ATA Annual Meeting
October 29, 2019 06:55 ET | Interpace Diagnostics Group, Inc.
PARSIPPANY, NJ, Oct. 29, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will be presenting new data on the performance of its molecular thyroid products at the upcoming 89th...
Logo.png
Interpace to Present at the American College of Gastroenterology Conference
October 24, 2019 06:55 ET | Interpace Diagnostics Group, Inc.
Interpace hosts 2nd Annual Fellow Programs PARSIPPANY, NJ, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Interpace (IDXG) announced today that it will be presenting new data on the performance of its...